Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

High-dose chemotherapy in multiple myeloma

H Goldschmidt¹, U Hegenbart, M Wallmeier

¹Department of Internal Medicine V, University of Heidelberg, Germany.

|January 22, 1998

Summary

High-dose chemotherapy with autologous stem cell transplantation significantly improves survival for multiple myeloma patients. This approach, using dose-escalated alkylating agents, offers better outcomes than conventional treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

Journal of cancer research and clinical oncology·2019

Same author

[Erratum to: First-line treatment of multiple myeloma].

Der Internist·2019

Same author

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Journal of internal medicine·2019

Area of Science:

Hematology
Oncology
Transplantation Medicine

Background:

Conventional chemotherapy for multiple myeloma offers limited survival benefits.
Dose-escalated alkylating agents show promise but are limited by toxicity.
Hematopoietic stem cell transplantation supports dose-escalated therapies.

Purpose of the Study:

To summarize results of transplantation trials in multiple myeloma.
To discuss prognostic factors and future treatment strategies.
To evaluate the survival advantage of autologous transplantation.

Main Methods:

Review of transplantation trials for multiple myeloma.
Analysis of randomized trials and pair-mate data.
Comparison of autologous peripheral blood progenitor cell vs. autologous bone marrow transplantation.

Related Experiment Videos

Main Results:

Dose-escalated alkylating agents achieve higher remission rates.
Autologous transplantation, particularly with peripheral blood stem cells, leads to faster recovery and reduced morbidity.
Significant survival advantage observed in patients undergoing autologous transplantation.

Conclusions:

Autologous stem cell transplantation is a key modality for improving survival in multiple myeloma.
Allogeneic transplantation's benefit is uncertain due to high mortality.
Further research into prognostic factors and novel treatments is warranted.